BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » cell therapy » Page 2

Mesenchymal Stem Cells Review | Future of MSC Therapy

July 1, 2018 By Cade Hildreth (CEO) 1 Comment

Mesenchymal Stem Cells Review

In this article, Dr. Daniel Kota provides a mesenchymal stem cell review and explores the future of MSC therapy. Mesenchymal stem cells (MSCs) are multipotent cells that prefer to differentiate into cells of the musculoskeletal system, such as bone, cartilage, muscle and fat cells. However, MSCs can also be induced to become other cell types, as well as exert therapeutic effects by honing to sites of repair and secreting therapeutic agents.

In this article:

  • Review of Mesenchymal Stem Cells (MSCs)
  • Challenges of Mesenchymal Stem Cells
  • Mesenchymal Stem Cell Therapy
  • Future Directions for Mesenchymal Stem Cells [Read more…]

Filed Under: MSCs Tagged With: cell therapy, MSC

Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility

April 10, 2018 By Cade Hildreth (CEO) Leave a Comment

  • First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases

  • With 300,000 square feet (27,870 square meters), it is the largest dedicated cell-and-gene-therapy manufacturing facility in the world

  • Facility to reach 200 full-time staff by end of 2018 and continue to recruit high-value positions as market demand increases

[Read more…]

Filed Under: Cell Therapy Tagged With: cell therapy, gene therapy, Lonza, manufacturing

SanBio’s Regenerative Medicine Product SB623 to Be Manufactured by Hitachi Chemical

March 13, 2018 By Cade Hildreth (CEO) Leave a Comment

March 13, 2018 03:39, TOKYO — SanBio Group and Hitachi Chemical Co., Ltd. (Hitachi Chemical) jointly announced today that, through an agreement with Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS; formerly PCT Cell Therapy Services, LLC), Hitachi Chemical’s US subsidiary that engages in contract manufacturing and development of regenerative medicine products*1, they will manufacture SB623, a proprietary regenerative medicine product under development by SanBio. Under the agreement, late stage clinical products and commercial products of SB623 for the US and Japanese markets will be manufactured using Hitachi Chemical’s global facilities. [Read more…]

Filed Under: Cell Therapy, Press Releases Tagged With: CDMO, cell therapy, SanBio

Cytori Completes Enrollment for Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function

January 22, 2018 By Cade Hildreth (CEO) Leave a Comment

  • Cytori developing cell therapies that harness the unique attributes of adipose-derived regenerative cells (ADRCs)

  • 40 patients enrolled among 5 French centers: Marseille, Montpelier, Rouen, Lyon, and Paris

SAN DIEGO, Jan. 22, 2018 — Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical trial intended to study the safety and efficacy of Habeo™ Cell Therapy in up to 40 subjects with impaired hand function due to scleroderma (systemic sclerosis). [Read more…]

Filed Under: Cell Therapy, Press Releases Tagged With: cell therapy, Cytori

2017 Marks the 1st Year That Regenerative Medicine Disrupted Healthcare

January 1, 2018 By Cade Hildreth (CEO) 1 Comment

Regenerative Medicine Industry

The regenerative medicine industry has been rapidly expanding over the past few years, making it a high-value, fast-growth market. Key drivers for the market include high rates of clinical trials, accelerated pathways for product approvals, new technologies to support cell and gene therapy manufacturing, and the potential for cell therapies to revolutionize healthcare.

The regenerative medicine market gained major momentum when the Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T cell therapy in the U.S. in August 2017 (Kymriah). In October 2017, Kite Pharma became the second company to get FDA approval of a CAR-T cell therapy (Yescarta).

With swelling momentum to support the CAR-T technology, there are now close to 40 companies developing redirected T cells or NK cells for therapeutic use. [Read more…]

Filed Under: CAR-T, Cell Therapy Tagged With: cell therapy, regenerative medicine

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 17
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    评分 0 / 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    评分 0 / 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    评分 0 / 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.